Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel
has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia 2 Flu + SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia 2
Fluorescent